DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its full-year 2025 financial results will be released after the markets close on Monday, March 30th. DiaMedica will host a live conference call on Tuesday, March 31stat 7:00 AM Central Time to provide a business update and discuss financial results.

Conference Call details:

Date: | Tuesday, March 31, 2026

Time: | 7:00 AM CDT / 8:00 AM EDT

Web access: | https://app.webinar.net/bxPLk6nkE0q

Dial In: | (646) 357-8766

Conference ID: | 4545194

Date:

Tuesday, March 31, 2026

Time:

7:00 AM CDT / 8:00 AM EDT

Web access:

Dial In:

(646) 357-8766

Conference ID:

4545194

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on the Company’s website, underinvestor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until April 7, 2026, by dialing (800) 770-2030 (US Toll Free) and entering the replay passcode: 4545194#.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website atwww.diamedica.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260323078631/en/

Scott KellenChief Financial OfficerPhone: (763) 496-5118skellen@diamedica.com

Source: DiaMedica Therapeutics Inc.

Released March 23, 2026